Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them una ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stoppi ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator:
Phone:
The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG). NCT number: NCT03971422 ... Read more >
Status: Enrolling
Investigator: Jason Thonhoff
Study Coordinator:
Phone:
The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator:
Phone:
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG). NCT number: NCT04124965 ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis. NCT Number:NCT03304054 ... Read more >
Status: Enrolling
Investigator: Sheetal Shroff
Study Coordinator:
Phone:
The primary objective of the study is: • To provide patients with CMS access to amifampridine phosphate therapy until the product becomes commercially available or development is discontinued. The secondary objective of the study is: • ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
Provide natural history data, biomarkers, and biological understanding of the phenotypic heterogeneity of myotonic dystrophy type 1 (DM1). ... Read more >
Status: Enrolling
Investigator: Jasleen Randhawa
Study Coordinator: Toniva Boone
Phone: 713.441.0686
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibod ... Read more >
Status: Open Not Enrolling
Investigator: Lisa Kopas
Study Coordinator:
Phone:
The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is c ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
Evaluate the long-term safety of amifampridine phosphate in the symptomatic relief of antibody positive MuSK-MG. NCT Number: NCT03579966 ... Read more >
Status: Open Not Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator:
Phone:
This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maint ... Read more >
Status: Enrolling
Investigator: Ericka Greene
Study Coordinator: Sharon Halton
Phone: 713.441.3420
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >
Status: Enrolling
Investigator: Ahmed Gaber
Study Coordinator: Isioma Agboli
Phone: 713.447.368
Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator:
Phone:
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >
